Fibrocell to Host Conference Call and Webcast on Tuesday, November 13, 2018 to Discuss Third Quarter 2018 Financial Results a...
November 08 2018 - 8:00AM
Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company
focused on transformational autologous cell-based therapies for
skin and connective tissue diseases, will report financial results
for the third quarter ended September 30, 2018 and recent
operational highlights on Tuesday, November 13, 2018 before the
open of the U.S. financial markets. Fibrocell will also host
a conference call and webcast at 8:30 a.m. EST on the same day to
discuss its financial results and operational highlights. A
question-and-answer session will follow Fibrocell’s remarks.
To participate on the live call, please dial
877-260-1479 (domestic) or +1-334-323-0522 (international), and
provide the conference code 7133925 five to ten minutes before
the start of the call. The conference call will also be webcast
live under the investor relations section of Fibrocell's website at
www.fibrocell.com/investors/events and will be archived there for
30 days following the call.
About Fibrocell
Fibrocell is an autologous cell and gene therapy
company translating personalized biologics into medical
breakthroughs for diseases affecting the skin and connective
tissue. Fibrocell’s most advanced product candidate, FCX-007,
is the subject of a Phase 1/2 clinical trial for the treatment of
recessive dystrophic epidermolysis bullosa. Fibrocell is also
developing FCX-013, the Company’s clinical stage candidate for the
treatment of moderate to severe localized
scleroderma. Fibrocell’s gene therapy portfolio is being
developed in collaboration with Precigen, Inc., a wholly owned
subsidiary of Intrexon Corporation (NASDAQ: XON), a leader in
synthetic biology. For more information, visit
www.fibrocell.com or follow Fibrocell on Twitter at @Fibrocell.
Trademarks
Fibrocell®, the Fibrocell logo, and Fibrocell
Science® are trademarks of Fibrocell Science, Inc. and/or its
affiliates. All other names may be trademarks of their
respective owners.
Investor & Media Relations Contact:Karen
Casey484-713-6133kcasey@fibrocell.com
Fibrocell Science (NASDAQ:FCSC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fibrocell Science (NASDAQ:FCSC)
Historical Stock Chart
From Apr 2023 to Apr 2024